ClinicalTrials.gg
RecruitingNCT07557589RFKPUpdated May 27, 2026

Radiofrequency Treatment for Pilonidal Disease : Clinical Investigation on Safety of Use, Efficacy and Patient Satisfaction at 6 Months

An interventional study of Radiofrequency treatment in Infected Pilonidal Sinus, sponsored by CHI MONT DE MARSAN ET PAYS DES SOURCES. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by CHI MONT DE MARSAN ET PAYS DES SOURCES · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Patient Satisfaction with a site in France — 16 open to participants now, 18 under way, none of them phase 3. Patient Satisfaction · France.

Planned enrollment
15th of 18
60 · median 132
Started
2026
with 3 others
No phase
17 of 43
11 open now
Primary completion
2027-01
later than 9 of 17 live
Registered
37th of 43
by date

Among the 43 studies in Patient Satisfaction with a site in France, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 37th registered.

Patient Satisfaction

882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.

Browse Patient Satisfaction studies →

Open to participants now

16 of the 43 studies in Patient Satisfaction with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Patient Satisfaction with a site in France, or all of them as a file.
02

Study summary

Infected pilonidal sinus is a common suppuration that occurs twice as often in men as in women, usually between the ages of 15 and 30. Clinical diagnosis is easy, whether the presentation is acute or chronic. Exeresis with a wound left open requiring secondary postoperative healing is the most widely practiced technique in France because its recurrence rate is the lowest, but it has the disadvantage of requiring daily or even twice-daily local nursing care, long healing, and a break in activity.

In order to limit the disadvantages of the open technique, "conservative" minimally invasive techniques have also recently been developed in response to strong patient demand: such as endoscopic treatment (EPSIT = Endoscopic Pilonidal Sinus Treatment, or VAAPS = Video-Assisted Ablation of Pilonidal Sinus), or the SiLaT (Sinus Laser Therapy) laser.

More recently, radiofrequency has emerged as a new technique in the treatment of hemorrhoidal pathology according to the Rafaelo procedure as well as the Fistura procedure for anal fistulas. The principle of the treatment is similar to that of the laser, based on radio frequency thermocoagulation using very high frequency electromagnetic waves (4MHz), similar to the principle of microwaves. However, its use in the infected pilonidal sinus has not yet been described. The fibers used in anal fistulas are perfectly adapted to the treatment of the pilonidal sinus. In addition, and in contrast to the laser, several fiber diameters are available depending on the size of the fistula path(s). For example, the large diameters of 9 Fr seem to be more adapted to the deep and wide cavities of the pilonidal sinuses than those of the SiLaT, which has a single fiber diameter. The investigators can therefore think that this type of fibers could allow a more efficient destruction of the granulation tissues and a better docking of the cavity walls.

According to published studies in the treatment of anal fistulas, the safety profile of this treatment is perfectly reassuring since the penetrance of the energy released does not exceed 3 mm in depth.

The aim of this study is to evaluate the radiofrequency treatment according to the Fistura® procedure, by mesure its safety, efficacy and patient satisfaction on a series of consecutive patients treated for infected sinus pilonidal.

03

Conditions studied

  • Infected Pilonidal Sinus

Browse trials for

Keywords

  • Infected Pilonidal Sinus
  • Radiofrequency
  • Safety
  • Efficacy
  • Patient Satisfaction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient presenting an infected pilonidal sinus at the exception of acute abscess stage requiring an surgical procedure
  • Patient aged 18 or above
  • For Women Of Child Bearing Age, use of efficient (less than 1% failure)
  • Patient with health insurance coverage
  • French-speaking patient
  • Patient who has given their free, informed and written consent

Exclusion criteria

Exclusion Criteria:

  • Patient already included in a type 1 interventional research protocol (RIPH1)
  • Patient with cardiac disease (including pacemaker)
  • Patient with skin infection
  • Patient with acute abcess
  • Patient with suppurated cavity requiring urgent drainage
  • Patient for whom local or general anesthesia is , with an anal infectious disease, or an anal fissure or who have previously had a stapled hemorrhoidopexy (Longo procedure) with metallic staples
  • Patient treated by aspririn or anticoagulant
  • Patient with bleeding or coagulation disorder
  • Allergic patient to nickel and chromium
  • Pregnant or Breastfeeding women
  • Patient under guardianship or curatorship
  • Patient incarcerated
  • Patient under legal protection
  • Patient refusing follow-up
  • Patient for whom MRI is contraindicated
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Radiofrequency using the Fistura procedure

    Radiofrequency using the Fistura procedure for treatment of infected pilonidal sinus

    Device: Radiofrequency treatment

Interventions

  • DeviceRadiofrequency treatment

    Radiofrequency using the Fistura procedure for treatment of infected pilonidal sinus

06

What researchers measure

Primary outcomes

  1. Evaluation of radiofrequency treatment safety

    Incidence rate of at least one complication of the radiofrequency treatment : incidence rate of of haemorrhagic complication, incidence rate of acute urinary retention and incidence rate of others complications such as post radiofrequency treatment abcess, haematoma, localized infection.

    Time frame: Within 15days after the radiofrequency treatment

Secondary outcomes

  1. Evaluation of radiofrequency treatment safety

    Incidence rate of of haemorrhagic complication after the radiofrequency treatment

    Time frame: Within 15days after the radiofrequency treatment

  2. Evaluation of radiofrequency treatment safety

    Incidence rate of acute urinary retention after the radiofrequency treatment

    Time frame: Within 15days after the radiofrequency treatment

  3. Evaluation of radiofrequency treatment safety

    Incidence rate of others complications such as post radiofrequency treatment abcess, haematoma, localized infection.

    Time frame: Within 15days after the radiofrequency treatment

  4. Evaluation of post radiofrequency pain

    Patient will be asked daily to evaluate post surgery pain using a Numerical Rating Scale (NRS). Patients will be asked to circle the number between 0 and 10 that fits best to their pain intensity. Zero represents 'no pain at all' whereas10 represents 'the worst pain ever possible'.

    Time frame: Within 15days after the radiofrequency treatment

  5. Evaluation of radiofrequency treatment efficiency

    During the last patient visit, a clinical evaluation will be performed during which closure of all existing fistula external opening will be assessed (Yes or No), as well as the absence or presence of abcess and new external opening (Yes or no) . The patient will be asked to evaluate the presence or absence of pain (yes or no) The Treatment will be evaluated as efficient if there is closure of all fistula external opening AND absence of pain AND absence of abscess or new external opening.

    Time frame: 6 months after the radiofrequency treatment

  6. Length of the medical leave after the radiofrequency treatment

    Record of number of medical leave days prescribed after the radiofrequency treatment Record of number of day after the radiofrequency treatmenty necessary before returning to normal activity.

    Time frame: Within 6 months after the radiofrequency treatment

  7. Measurement of patient satisfaction after the radiofrequency treatment

    Each patient will evaluate their satisfaction regarding their radiofrequency treatment using a visual 5 point scale ranking from "very unsatified" to "very satisfied"

    Time frame: At 1 mont and 6 months after the radiofrequency treatment

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Merlini l'Heritier A, Siproudhis L, Bessi G, Le Balc'h E, Wallenhorst T, Bouguen G, Brochard C. Sphincter-sparing surgery for complex anal fistulas: radiofrequency thermocoagulation of the tract is of no help. Colorectal Dis. 2019 Aug;21(8):961-966. doi: 10.1111/codi.14618. Epub 2019 Apr 3. PubMed 30897291 ↗
  • Spindler L, Alam A, Fathallah N, Rentien AL, Draullette M, Pommaret E, Thierry ML, Mituialy AE, Abbes L, Aubert M, Benfredj P, Far ES, Beaussier H, de Parades V. Extensive suppuration and being overweight are factors associated with the failure of laser treatment for pilonidal disease: lessons from the first French retrospective cohort. Tech Coloproctol. 2022 Feb;26(2):143-146. doi: 10.1007/s10151-021-02552-2. Epub 2021 Dec 2. PubMed 34855026 ↗
  • Keogh KM, Smart NJ. The proposed use of radiofrequency ablation for the treatment of fistula-in-ano. Med Hypotheses. 2016 Jan;86:39-42. doi: 10.1016/j.mehy.2015.11.019. Epub 2015 Nov 26. PubMed 26804594 ↗
  • Eddama MMR, Everson M, Renshaw S, Taj T, Boulton R, Crosbie J, Cohen CR. Radiofrequency ablation for the treatment of haemorrhoidal disease: a minimally invasive and effective treatment modality. Tech Coloproctol. 2019 Aug;23(8):769-774. doi: 10.1007/s10151-019-02054-2. Epub 2019 Aug 9. PubMed 31399891 ↗
  • Dessily M, Charara F, Ralea S, Alle JL. Pilonidal sinus destruction with a radial laser probe: technique and first Belgian experience. Acta Chir Belg. 2017 Jun;117(3):164-168. doi: 10.1080/00015458.2016.1272285. Epub 2017 Jan 6. PubMed 28056720 ↗
  • Sluckin TC, Hazen SJA, Smeenk RM, Schouten R. Sinus laser-assisted closure (SiLaC(R)) for pilonidal disease: results of a multicentre cohort study. Tech Coloproctol. 2022 Feb;26(2):135-141. doi: 10.1007/s10151-021-02550-4. Epub 2022 Jan 7. PubMed 34993686 ↗
  • Romic I, Augustin G, Bogdanic B, Bruketa T, Moric T. Laser treatment of pilonidal disease: a systematic review. Lasers Med Sci. 2022 Mar;37(2):723-732. doi: 10.1007/s10103-021-03379-x. Epub 2021 Jul 22. PubMed 34291332 ↗
  • Meinero P, La Torre M, Lisi G, Stazi A, Carbone A, Regusci L, Fasolini F. Endoscopic pilonidal sinus treatment (EPSiT) in recurrent pilonidal disease: a prospective international multicenter study. Int J Colorectal Dis. 2019 Apr;34(4):741-746. doi: 10.1007/s00384-019-03256-8. Epub 2019 Feb 4. PubMed 30719564 ↗
  • Velotti N, Manigrasso M, Di Lauro K, Araimo E, Calculli F, Vertaldi S, Anoldo P, Aprea G, Simone G, Vitiello A, Musella M, Milone M, De Palma GD, Milone F, Sosa Fernandez LM. Minimally Invasive Pilonidal Sinus Treatment: A Narrative Review. Open Med (Wars). 2019 Aug 7;14:532-536. doi: 10.1515/med-2019-0059. eCollection 2019. PubMed 31428682 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 368 non-industry interventional studies with no phase under Patient Satisfaction, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 9 months is below that.

Counting every sponsor, half of 370 studies reached it within 12 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07557589
Lead sponsor
CHI MONT DE MARSAN ET PAYS DES SOURCES
Collaborators
Centre Hospitalier de Dax
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Apr 24, 2026
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
May 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion